And the results indicated that poor responders had significantly lower EPA and plasma levels of EPA in baseline than good responders, suggesting that late-stage AMD patients with low plasma EPA concentrations may require treatment other than anti-VEGF in the early stage. This evidence concerns the gene VEGFA and age-related macular degeneration.